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Aims: Because of the prognostic importance of LV dysfunction following an AMI and the increasing use of electrical and/or mechanical
interventions in patients with LV systolic dysfunction, this retrospective analysis of EPHESUS patients with LVEF 30% at baseline was
conducted to determine the value of eplerenone in this setting.
Methods and results: In EPHESUS, 6632 patients with LVEF 40% and clinical heart failure (HF) post-AMI who were receiving standard
therapy were randomized to eplerenone 25 mg/day titrated to 50 mg/day or placebo for a mean follow-up of 16 months. Treatment with
eplerenone in the subgroup of patients with LVEF 30% (N =2106) resulted in relative risk reductions of 21% versus placebo in both all-
cause mortality (P=0.012) and cardiovascular (CV) mortality/CV hospitalization (P=0.001), and 23% for CV mortality (P=0.008). The
relative risk of sudden cardiac death (SCD) was reduced 33% (P=0.01) and HF mortality/HF hospitalization was reduced 25% (P=0.005)
with eplerenone compared with placebo. Within 30 days of randomization, eplerenone resulted in relative risk reductions of 43% for all-cause
mortality (P=0.002), 29% for CV mortality/CV hospitalization (P=0.006), and 58% for SCD (P=0.008).
Conclusions: Treatment with eplerenone plus standard therapy in patients with post-AMI HF and LVEF 30% provided significant
incremental benefits in reducing both early and late mortality and morbidity.
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The Eplerenone Post-acute Myocardial Infarction Heart
Failure Efficacy and Survival Study (EPHESUS) [1]1388-9842/$ - see front matter D 2005 European Society of Cardiology. Publishe
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E-mail address: bpitt@med.umich.edu (B. Pitt).demonstrated the efficacy of eplerenone in addition to
standard therapy in reducing all-cause mortality, sudden
cardiac death, cardiovascular (CV) mortality/CV hospitali-
zation, the incidence of hospitalization for heart failure, and
heart failure mortality/heart failure hospitalization in
patients with left ventricular ejection fraction (LVEF)
40% and clinical evidence of heart failure post-acuteFailure 8 (2006) 295 – 301d by Elsevier B.V. All rights reserved.
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treatment was initiated between 3 and 14 days (mean, 7.3
days) post-AMI.
There is increasing evidence of the prognostic importance
of left ventricular dysfunction post-AMI. In particular, there
is an increased risk for early as well as late sudden cardiac
death, and death and hospitalization due to heart failure in
those patients with LVEF30% post-AMI [2]. For example,
a recent analysis of 14,609 patients with left ventricular
systolic dysfunction (LVEF 40%), heart failure, or both
after AMI found that each 5% decrease in LVEF was
associated with a 21% increase in the risk of sudden
unexpected death or cardiac arrest with resuscitation in the
first 30 days following an AMI [3]. In patients with LVEF
30%, there was a 2.3% incidence of sudden death or
cardiac arrest with resuscitation during the first 30 days post-
infarction, compared with a 1.4% incidence in all patients
during this timeframe. Overall, 19% of all sudden death or
cardiac arrest occurred within the first 30 days post-
infarction, and 54% of these events occurred in patients with
LVEF30%. This increased early risk in patients with LVEF
30% persisted over the long term despite routine treatment
with angiotensin-converting enzyme (ACE) inhibitors/an-
giotensin receptor blockers (ARBs) and h-blockers [3].
Patients with severely reduced LVEF following AMI
have an increased need for implantation of electrical and/or
mechanical devices, which has important health care cost
implications [4,5]. Unfortunately, current evidence demon-
strates that these devices are not beneficial in reducing
mortality in the immediate post-infarction period, the time
of highest risk in these patients [6]. Based on these
considerations, we have performed a retrospective analysis
of the subset of EPHESUS patients with a baseline LVEF
of 30%, representing approximately one-third of the
overall EPHESUS population, to provide insight into the
potential importance of using selective aldosterone block-
ade with eplerenone for preventing early and late all-cause
mortality, sudden cardiac death, and heart failure mortality/
heart failure hospitalization in this high-risk population
and, therefore, its potential to impact the need for electrical
and/or mechanical interventions in these patients.2. Methods
2.1. Study design and study population
EPHESUS was a multicenter, international, randomized,
double-blind, placebo-controlled trial, which has been
described previously [1]. Stable patients with left ventricular
systolic dysfunction (LVSD), documented by LVEF 40%,
and heart failure, diagnosed clinically by the presence of
pulmonary rales, pulmonary vascular congestion on chest
radiography, or the presence of a third heart sound, who
were receiving standard optimal therapy were eligible for
randomization 3 to 14 days after AMI (N =6632). LVEFwas measured and analyzed at the study site by echocar-
diogram, radionuclide angiography, or left ventricular
angiography. Patients were randomized to receive either
eplerenone (25 mg/day) or placebo for 4 weeks. The
eplerenone dose was increased in a single step to 50 mg/
day at week 4 if tolerated; the final mean dose was 43 mg/
day. Follow-up visits were scheduled at 1 and 4 weeks, 3
months, and every 3 months thereafter until the study ended.
Patients were followed for up to 2.5 years, with a mean
follow-up of 16 months.
Symptoms of heart failure were not necessary for study
inclusion among patients with diabetes mellitus and LVSD
post-AMI; diabetic patients with LVSD but without heart
failure comprised about one-third of the diabetic patients
and about 10% of the entire study population. Exclusion
criteria for the entire study population included the use of
potassium-sparing diuretics, a serum creatinine concentra-
tion greater than 2.5 mg/dl (220 Amol/l), or a serum
potassium concentration greater than 5.0 mmol/l.
The mean age of the overall population in EPHESUS
was 64T11.5 years; mean LVEF was 33%T6%. At baseline,
87% of EPHESUS patients were receiving ACE inhibitors
or ARBs; 75%, h-blockers; 60%, diuretics; 88%, aspirin;
47%, statins; and 45% had received pre-randomization
reperfusion therapy (thrombolysis, angioplasty, or coronary
artery bypass grafts).
2.2. Study end points
The end points assessed in this subgroup analysis of the
EPHESUS trial included the 2 primary study end points:
time to all-cause mortality and time to first occurrence of the
composite of CV mortality/CV hospitalization. CV hospi-
talization was defined as hospitalization for heart failure,
recurrent AMI, stroke, or ventricular arrhythmia. Other
efficacy variables assessed included sudden cardiac death,
and the composite end point of death due to progressive
heart failure or nonfatal hospitalization for heart failure. In
addition to the findings at mean 16-month follow-up, results
for each of these end points also were examined 30 days
post-randomization.
2.3. Statistical analysis
This analysis evaluated the treatment effects in the
subgroup of patients with LVEF 30%, based on the
time to the first occurrence of an event. Results were
based on a proportional hazards model stratified by
region with treatment as factor. Ninety-five percent
confidence intervals (CI) were based on the Wald test.
The between-treatment comparisons were based on the
log-rank test stratified by geographical region. The
between-treatment comparison of the number of episodes
of nonfatal heart failure hospitalizations was based on a
Cochran–Mantel–Haenszel test stratified by region. All
reported P values were 2-sided. The between-treatment
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on Fisher’s Exact Test.3. Results
3.1. Study patients
The subgroup of EPHESUS patients with LVEF 30%
totaled 2106 (32% of the overall population). Of these, 1048
received eplerenone and 1058 received placebo. Baseline
characteristics were comparable between the treatment
groups (Table 1).
Similar to the overall EPHESUS population [1], the
majority of patients in both treatment groups were receiving
standard treatment with ACE inhibitors, h-blockers, aspirin,
diuretics, and statins at baseline, and nearly half of each
subgroup had undergone coronary reperfusion. More patients
in the LVEF 30% group had a history of diabetes, heart
failure, and MI than in the overall EPHESUS population [1].
Hemodynamic changes at 1 year in the EPHESUS
patients with LVEF 30% included a mean increase inTable 1
Baseline characteristics of EPHESUS patients with LVEF 30%
Characteristic Eplerenone Placebo
n =1048 n =1058
Age (years) 65T11 65T12
Sex, n (%)
Male 777 (74) 752 (71)
Female 271 (26) 306 (29)
Race, n (%)
Caucasian 914 (87) 922 (87)
Black 14 (1) 18 (2)




LVEF (%) 26T4 26T5
Serum creatinine (mg/dl) 1.2T0.4 1.2T0.4
Serum potassium (mmol/l) 4.3T0.5 4.2T0.5

















Plus–minus values represent meanTSD.
ACEI—angiotensin-converting enzyme inhibitor; AMI—acute myocardial
infarction; ARB—angiotensin receptor blocker; LVEF—left ventricular
ejection fraction.systolic blood pressure (SBP) of 4.7 mm Hg with
eplerenone versus an increase of 7.6 mm Hg (P=0.004)
with placebo and a mean increase in diastolic blood pressure
(DBP) of 3.0 mm Hg with eplerenone versus an increase of
3.6 mm Hg with placebo (P >0.20). The mean decrease in
sitting pulse rate was 7.8 beats per minute with eplerenone
versus 7.3 beats per minute with placebo (P=0.162). At 30
days, increases in blood pressure in eplerenone- and
placebo-treated patients were 1.5 mm Hg and 3.2 mm Hg
for SBP (P=0.069), and 1.6 mm Hg and 2.4 mm Hg for
DBP (P=0.080), respectively.
3.2. End points
Compared with the overall placebo-treated EPHESUS
population, placebo-treated patients with LVEF 30% had
a higher incidence of all-cause death (24.0% versus
16.7%), CV mortality/CV hospitalization (40.9% versus
30.0%), and sudden cardiac death (9.7% versus 6.1%).
Among all EPHESUS patients with LVEF 30%, a total
of 254 patients (24.0%) in the placebo group versus 205
patients (19.6%) treated with eplerenone died (Fig. 1A), a
relative risk reduction of 21% (P=0.012) with eplerenone
(Table 2). (In the entire EPHESUS population, the relative
risk reduction for all-cause mortality was 15% with
eplerenone [P=0.008]). For the composite end point of
CV mortality/CV hospitalization in patients with LVEF
30%, eplerenone reduced the relative risk by 21% versus
placebo (P=0.001) (Fig. 1B). (The relative risk reduction
for this end point was 13% in the entire EPHESUS
population [P=0.002]). For the end point of CV mortality,
eplerenone reduced the relative risk by 23% compared
with placebo (P=0.008) in patients with LVEF 30%;
this compares to a relative risk reduction of 17% with
eplerenone in the entire EPHESUS population (P=0.005).
The relative risk of sudden cardiac death in EPHESUS
patients with LVEF 30% was reduced by 33% (P=0.01)
among patients treated with eplerenone compared with
those treated with placebo (Fig. 1C). (Among the entire
EPHESUS population, relative risk reduction for sudden
cardiac death was 21% with eplerenone compared with
placebo [P=0.03]).
The relative risk for the composite end point of death
due to progressive heart failure or nonfatal hospitalization
for heart failure in EPHESUS patients with LVEF 30%
was reduced with eplerenone by 25% ( P =0.005)
compared with placebo. The number of patients who
experienced nonfatal hospitalization for heart failure was
reduced by 20% with eplerenone (P=0.037) and death
due to progressive heart failure was reduced by 19% with
eplerenone (P =0.277) (Table 2). There were 216
episodes of nonfatal hospitalizations for heart failure in
eplerenone-treated patients versus 296 episodes with
placebo, a reduction of 27% (P=0.015). (In the overall
EPHESUS population, the number of episodes of nonfatal
hospitalizations for heart failure was reduced by 23%
Fig. 1. Kaplan–Meier estimates of the cumulative incidence of (A) all-cause mortality, (B) CV mortality/CV hospitalization, and (C) sudden cardiac death in
EPHESUS patients with LVEF 30%.
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hospitalized for heart failure was reduced by 15%
[P=0.03]).Within 30 days of randomization, eplerenone demon-
strated significant risk reductions in EPHESUS patients with
LVEF 30%, including relative risk reductions of 43% for
Table 2
Summary of primary and secondary end points in EPHESUS patients with LVEF 30%
Event, n (%) Eplerenone Placebo Risk ratio P Value
n =1048 n =1058
n (%) n (%)
All-cause mortality 205 (19.6) 254 (24.0) 0.79 0.012
CV mortality/CV hospitalization 359 (34.3) 433 (40.9) 0.79 0.001
CV mortality 177 (16.9%) 226 (21.4%) 0.77 0.008
Sudden cardiac death 71 (6.8) 103 (9.7) 0.67 0.01
Death due to progressive heart failure/
nonfatal hospitalization for heart failure
176 (16.8) 221 (20.9) 0.75 0.005
Nonfatal hospitalization for heart failure 152 (14.5) 181 (17.1) 0.80 0.037
Death due to progressive heart failure 49 (4.7) 59 (5.6) 0.81 0.277
CV—cardiovascular.
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tion, and 58% for sudden cardiac death (Fig. 2).
3.3. Safety
Treatment with eplerenone was safe and well tolerated.
The incidence of adverse events was similar in eplerenone-
treated and placebo-treated patients with LVEF 30%,
except as noted below for changes in serum potassium, and
did not differ from those reported in each respective
treatment group for the overall population [1].
Among patients with LVEF30%, serious hyperkalemia,
defined as serum potassium (K+) 6.0 mmol/l, occurred in
3.5% of placebo-treated patients and 5.9% of eplerenone-
treated patients, an absolute increase of 2.4% (P=0.01) with
eplerenone; this compares with a 1.6% increase in serious
hyperkalemia observed in the main EPHESUS findings.
Hypokalemia (K+3.5 mmol/l) occurred in 14.8% of
placebo-treated patients versus 7.5% of eplerenone-treated
patients, an absolute decrease of 7.3% (P <0.001) with








Fig. 2. Relative risks of mortality and morbidity at 30 days post-randomization in E
confidence intervals.were no deaths adjudicated to hyperkalemia in eplerenone-
treated patients, and 1 death attributed to hyperkalemia
among placebo-treated patients (all deaths in EPHESUSwere
adjudicated by a blinded, independent panel).4. Discussion
The results of this analysis suggest an important role for
eplerenone both in the early (30 days) as well as late
prevention of all-cause mortality, sudden cardiac death, and
heart failure mortality/heart failure hospitalizations in
patients with heart failure post-AMI and baseline LVEF
30% (Table 2, Figs. 1 and 2). These findings are of
particular importance because patients with severely re-
duced ejection fraction have a high incidence of sudden
death, death due to progressive heart failure, and all-cause
mortality [3]. These results are especially important in view
of the recent findings from the Defibrillator in Acute
Myocardial Infarction Trial (DINAMIT) [6], which indicate
that automatic implantable cardioverter/defibrillator (ICD)1.0 1.2 1.4 1.6 1.8
r Placebo Better























PHESUS patients with LVEF 30%. Data represent hazard ratios and 95%
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beneficial in reducing all-cause mortality.
The importance of eplerenone in decreasing all-cause
mortality in patients early post-infarction with evidence of
LVSD and signs of clinical heart failure is further empha-
sized by the failure of the ARB valsartan to reduce mortality
or morbidity when added to conventional therapy including
an ACE-inhibitor and a h-blocker under similar circum-
stances [7]. Thus, eplerenone in addition to standard therapy
including reperfusion, aspirin, a statin, an ACE inhibitor or
ARB, and a h-blocker could provide an important compo-
nent of therapy to prevent both early and late all-cause
mortality post-AMI in patients with decreased LVEF.
Studies in animal models of heart failure post-infarction
have shown aldosterone blockade to be effective in attenu-
ating ventricular remodeling and myocardial collagen for-
mation, and have suggested that the combination of an ACE
inhibitor or an ARBwith an aldosterone blocker may bemore
effective than either alone in improving LVEF post-infarction
[8]. The effectiveness of aldosterone blockade in attenuating
ventricular remodeling also has been demonstrated in several
studies in patients with chronic heart failure and LVSD due to
nonischemic cardiomyopathy [9]. Of particular interest is the
study by Rodriguez et al. [10], which demonstrated that in
patients with AMI randomized to placebo, ramipril, or
spironolactone, those assigned to either an ACE inhibitor or
an aldosterone blocker did not develop left ventricular
dilatation at 6 months compared with placebo patients, in
whom increases in LVend-systolic and end-diastolic volumes
occurred. Similar findings have been reported by Hayashi et
al. [11], in patients with a first anterior myocardial infarction
who were randomized to an aldosterone-blocking strategy
with intravenous canrenoate on the day of admission and oral
spironolactone thereafter, or to no aldosterone-blocking
therapy. Starting on day 1 post-infarction following primary
percutaneous transluminal coronary angioplasty (PTCA), all
patients received an ACE inhibitor and aspirin, while h-
blockers, diuretics, and other common cardiac medications
were given as needed. Patients in that study had a mean
baseline LVEF of approximately 47%. Those randomized to
the aldosterone-blocking strategy had a significant increase in
their LVEF at 1 month post-infarction compared with those
randomized to placebo. Therefore, it appears that early
administration of an aldosterone-blocking agent post-infarc-
tion to patients with an LVEF of30% could improve LVEF
and attenuate adverse left ventricular remodeling.
The exact incidence of persistent LVSD and the incidence
of cardiac death in those with persistent LVSD (LVEF30%
for longer than 1 month) in EPHESUS cannot be determined
because LVEF was consistently measured only prior to
randomization, which occurred at a mean of 7.3 days post-
infarction. However, it is likely that LVEF had improved to
greater than 30% at 1 month in many patients due to the
effects of reperfusion, recovery from myocardial stunning
and hibernation, as well as the effects of ACE inhibition, h-
blockade, and eplerenone on ventricular remodeling.While the effects of eplerenone in preventing ventricular
remodeling and myocardial collagen formation are likely
important in preventing the development of progressive
heart failure, it is likely that other mechanisms are of
importance in explaining its effectiveness in reducing
sudden cardiac death. Aldosterone blockade has important
effects on the production of reactive oxygen species (ROS)
by reducing NAD(P)H oxidase in the vascular wall and
myocardium, and oxidized low-density lipoprotein choles-
terol in circulating macrophages [12,13]. The production of
ROS and the consequent destruction of nitric oxide have
been shown to increase the release of norepinephrine from
sympathetic nerve terminals and decrease heart rate vari-
ability [14]. Restoration of nitric oxide reduces norepineph-
rine release, improves heart rate variability, and baroreceptor
function [15]. Aldosterone blockade has been shown to
improve the availability of nitric oxide [16], improve
myocardial norepinephrine uptake and hence decrease
circulating catecholamine levels [17], shorten QTC intervals
[18], improve heart rate variability [19], and decrease
ventricular arrhythmias in patients with chronic heart failure
[17]. As mentioned above, aldosterone blockade also
attenuates ventricular remodeling post-AMI, and, therefore,
could be expected to reduce the activation of neuro-
hormones such as angiotensin II and endothelin in the
circulation and myocardial tissue. This should result in a
further reduction in growth factors, cytokines, and inflam-
matory markers that also play an important role in ROS
production and sudden cardiac death.
Aldosterone blockade also has been shown to have an
effect on serum electrolytes, and more importantly, tissue
electrolytes, including potassium, magnesium, and calcium.
Recent data suggest that mineralocorticoid receptors in the
endothelium could play an important role in electrolyte
balance in that aldosterone results in sodium retention,
endothelial swelling, and loss of potassium, whereas
aldosterone blockade prevents endothelial sodium accumu-
lation and cell swelling and increases intramyocardial
potassium levels [20]. AMI has recently been shown to
cause electrical remodeling of the myocardium, with an
increase in intramyocardial calcium current (ICa), a decrease
in potassium outward current (Ito), and a prolongation of
action potential duration prior to the development of
myocyte hypertrophy [21]. The early changes in electrical
remodeling can be prevented by blockade of the mineralo-
corticoid receptor [21]. It is likely that the early reduction of
sudden cardiac death associated with the use of eplerenone
in this study was due to its effects on electrical remodeling
rather than its effects on ventricular remodeling. Regardless
of the exact mechanism, there is increasing evidence for the
effectiveness of aldosterone blockade in preventing sudden
cardiac death as well as death due to progressive heart
failure and, hence, overall mortality in patients with LVSD
both post-AMI [1] and with chronic heart failure [22].
As in the overall trial, there was no increase in the
incidence of breast pain, gynecomastia, or impotence in
B. Pitt et al. / The European Journal of Heart Failure 8 (2006) 295–301 301males or abnormal vaginal bleeding in females, attesting to
the selectivity of eplerenone for the mineralocorticoid
receptor in comparison to spironolactone. There was,
however, a 2.4% increase in the risk of serious hyperkalemia
(K+6.0 mmol/l) in patients randomized to eplerenone
compared to those randomized to placebo in this subset with
an LVEF 30% at baseline, compared with a 1.6% increase
in the eplerenone group in the overall study. However, as
emphasized in the original report of EPHESUS, the effect of
eplerenone on total mortality was favorable and there were no
deaths attributed to hyperkalemia in eplerenone-treated
patients; the single death in EPHESUS that was attributable
to hyperkalemia occurred in a patient randomized to placebo.
It is however important to emphasize that in EPHESUS
efforts were made to avoid serious hyperkalemia by
excluding patients with a baseline serum potassium 5.0
mmol/l and/or serum creatinine >2.5 mg/dl, routine moni-
toring of serum potassium, reducing the dose of eplerenone in
any patient in whom serum potassium rose above 5.5 mmol/l,
and discontinuing therapy in any patient whose serum
potassium reached 6.0 mmol/l in the absence of any
precipitating factor (such as the use of a nonsteroidal anti-
inflammatory drug; potassium supplement; or intercurrent
illness affecting volume, such as diarrhea or vomiting). Thus,
it appears from this analysis, as well as that from the overall
EPHESUS trial, that the beneficial effects of eplerenone, if
used with the inclusion criteria and potassium-monitoring
strategy outlined above, outweigh any potential risk of
serious hyperkalemia and that, unless contraindicated be-
cause of hyperkalemia or severe renal dysfunction, epler-
enone should be considered for use in all patients with
baseline LVSD and signs of heart failure post-AMI,
especially those with baseline LVEF 30%.References
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